Bioharvest Sciences (BHST) Common Equity (2023 - 2025)

Bioharvest Sciences' Common Equity history runs 3 years deep, the most recent figure standing at $25.4 million for Q4 2025.

• In Q4 2025, Common Equity rose 1813.38% year-over-year to $25.4 million; the TTM figure through Dec 2025 stood at $25.4 million (up 1813.38% YoY), while the FY2025 annual figure was $25.4 million, up 1813.38% from the prior year.
• Common Equity was $25.4 million for Q4 2025 at Bioharvest Sciences, up from $7.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $25.4 million in Q4 2025 to a low of -$83.5 million in Q4 2023.
• Historically, Common Equity has averaged -$6.1 million across 3 years, with a median of $4.1 million in 2024.
• Biggest YoY gain for Common Equity was 1813.38% in 2025; the steepest drop was 163.01% in 2025.
• A 3-year view of Common Equity shows it stood at -$83.5 million in 2023, then jumped by 101.59% to $1.3 million in 2024, then surged by 1813.38% to $25.4 million in 2025.
• The last three Common Equity figures came in at $25.4 million (Q4 2025), $7.7 million (Q3 2025), and -$4.2 million (Q2 2025), per Business Quant data.